ArticleEuropean thyroid journal2026
CD8+ T cells in Hashimoto's thyroiditis-associated papillary thyroid carcinoma.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy and frequently coexists with Hashimoto's thyroiditis (HT). Clinical observations indicate that HT-PTC tends to display less aggressive clinicopathological features; however, the immune characteristics underlying this phenomenon remain incompletely defined. In this study, we combined transcriptomic analysis with experimental validation to investigate CD8+ T cell features in HT-PTC. Analysis of TCGA data showed increased CD8+ T cell infiltration in HT-PTC compared with non-HT-PTC. In surgically resected specimens from our center, primary CD8+ T cells derived from HT-PTC were further characterized. Tumor-derived CD8+ T cells maintained cytokine secretion capacity and showed lower expression of TIM-3 and LAG-3, together with higher Granzyme B levels. In coculture assays, these cells were associated with reduced proliferation and migration of thyroid cancer cells. Overall, CD8+ T cells in HT-PTC exhibited no pronounced exhaustion-associated feature pattern and retained functional activity. This immune profile may be linked to the relatively less aggressive behavior observed in HT-PTC and provides a biological reference for future immune-informed risk stratification strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.